// App-Quantinova.ai

2030 : The role of genetic variation in calcium-activated potassium channels in breast cancer patients treated with tamoxifen

Researchers

Presenter

  • Wing-Yee Lo

Principal Investigators

  • Corinna Mohr

  • Friederike Steudel

  • Marjanka Schmidt

  • Douglas Easton

  • Reiner Hoppe

  • Werner Schroth

  • Peter Ruth

  • Robert Lukowski

  • Hiltrud Brauch

Medical Centers

  • Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tubingen, Stuttgart, Germany

  • Department of Pharmacology, Toxicology and Clinical Pharmacy, University of Tuebingen, Tuebingen, Germany

  • The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands

  • Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom

  • Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, University of Tuebingen, Tuebingen, and German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Locations

  • Germany

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Breast cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Tamoxifen

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved